Smith & Nephew SNATS ROE 2006-2018 | SNN

Current and historical return on equity (ROE) values for Smith & Nephew SNATS (SNN) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Smith & Nephew SNATS ROE for the three months ending December 31, 2018 was 0.00%.
Smith & Nephew SNATS ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2014-12-31 $0.50B $4.04B 12.20%
2014-09-30 $0.50B $4.02B 12.24%
2014-06-30 $0.52B $4.16B 12.81%
2014-03-31 $0.56B $4.22B 14.01%
2013-12-31 $0.56B $4.05B 14.07%
2013-09-30 $0.54B $3.91B 13.71%
2013-06-30 $0.55B $3.90B 14.26%
2013-03-31 $0.71B $3.95B 18.91%
2012-12-31 $0.73B $3.88B 20.06%
2012-09-30 $0.73B $3.64B 21.01%
2012-06-30 $0.73B $3.56B 21.91%
2012-03-31 $0.59B $3.45B 18.30%
2011-12-31 $0.58B $3.19B 18.80%
2011-09-30 $0.62B $3.06B 20.86%
2011-06-30 $0.63B $3.13B 22.06%
2011-03-31 $0.61B $3.00B 23.17%
2010-12-31 $0.62B $2.77B 25.14%
2010-09-30 $0.56B $2.48B 24.41%
2010-06-30 $0.55B $2.31B 25.31%
2010-03-31 $0.53B $2.23B 25.71%
2009-12-31 $0.47B $2.18B 24.28%
2009-09-30 $0.46B $2.01B 25.17%
2009-06-30 $0.41B $1.88B 22.95%
2009-03-31 $0.39B $1.71B 22.33%
2008-12-31 $0.38B $1.70B 21.17%
2008-09-30 $0.36B $1.77B 20.05%
2008-06-30 $0.30B $1.81B 16.36%
2008-03-31 $0.31B $1.81B 16.04%
2007-12-31 $0.32B $1.82B 15.73%
2007-09-30 $0.36B $1.91B 16.92%
2007-06-30 $0.44B $2.16B 20.33%
2007-03-31 $0.42B $2.16B 20.15%
2006-12-31 $0.75B $2.17B 36.93%
2006-09-30 $0.70B $2.07B 37.12%
2006-06-30 $0.67B $2.01B 38.78%
2006-03-31 $0.67B $1.89B 42.18%
2005-12-31 $0.34B $1.57B 23.26%
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $19.274B $4.904B
Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physicianadvantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment todeliver new levels of healing to patients throughout the world
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $147.856B 28.70
Medtronic (MDT) Ireland $133.874B 19.12
Stryker (SYK) United States $76.669B 27.36
Boston Scientific (BSX) United States $59.033B 28.30
Baxter (BAX) United States $41.839B 26.37
EssilorLuxottica Societe Anonyme (ESLOY) France $29.060B 0.00
Coloplast (CLPBY) Denmark $25.618B 40.90
Zimmer Biomet Holdings (ZBH) United States $24.965B 16.04
Lonza Group Ag (LZAGY) Switzerland $24.947B 0.00
Terumo (TRUMY) Japan $23.393B 26.90
ResMed (RMD) United States $17.745B 33.90
Canopy Growth (CGC) Canada $12.161B 0.00
Sunny Optical Technology (SNPTF) China $12.027B 0.00
Bio-Rad Laboratories (BIO) United States $9.308B 49.34
William Demant Holdings (WILYY) Denmark $7.651B 0.00
Insulet (PODD) United States $7.203B 524.78
Aurora Cannabis (ACB) Canada $7.109B 70.10
Perrigo (PRGO) Ireland $7.004B 11.84
Hill-Rom Holdings (HRC) United States $6.993B 21.20
GN STORE NORD (GNNDY) Denmark $6.409B 32.73
Haemonetics (HAE) United States $6.325B 51.63
ICU Medical (ICUI) United States $5.135B 30.64
GW Pharmaceuticals (GWPH) United Kingdom $5.057B 0.00
Neogen (NEOG) United States $3.349B 54.45
NuVasive (NUVA) United States $2.982B 24.36
Hutchison China MediTech (HCM) China $2.925B 0.00
Agios Pharmaceuticals (AGIO) United States $2.711B 0.00
National Vision Holdings (EYE) United States $2.420B 51.57
Quidel (QDEL) United States $2.309B 23.96
Cardiovascular Systems (CSII) United States $1.598B 917.80
Aphria (APHA) $1.579B 0.00
Phibro Animal Health (PAHC) United States $1.229B 18.41
AtriCure (ATRC) United States $1.218B 0.00
VAREX IMAGING (VREX) United States $1.187B 25.19
Lantheus Holdings (LNTH) United States $1.089B 28.93
NanoString Technologies (NSTG) United States $1.056B 0.00
PetIQ (PETQ) United States $0.994B 24.14
MacroGenics (MGNX) United States $0.777B 0.00
Eagle Pharmaceuticals (EGRX) United States $0.765B 21.47
Cerus (CERS) United States $0.758B 0.00
Quanterix (QTRX) United States $0.753B 0.00
Omeros (OMER) United States $0.750B 0.00
TG Therapeutics (TGTX) United States $0.698B 0.00
LeMaitre Vascular (LMAT) United States $0.572B 27.71
Surmodics (SRDX) United States $0.543B 78.88
OraSure Technologies (OSUR) United States $0.531B 24.43
Meridian Bioscience (VIVO) United States $0.476B 14.56
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.404B 0.00
Vapotherm (VAPO) United States $0.345B 0.00
Utah Medical Products (UTMD) United States $0.320B 22.13
BioLife Solutions (BLFS) United States $0.304B 95.24
Zynex (ZYXI) United States $0.250B 25.67
Bovie Medical (APYX) United States $0.236B 0.00
Cytosorbents (CTSO) United States $0.227B 0.00
Owens & Minor (OMI) United States $0.198B 4.20
Chimerix (CMRX) United States $0.188B 0.00
United Health Products (UEEC) United States $0.175B 0.00
Rockwell Medical (RMTI) United States $0.170B 0.00
Female Health (VERU) United States $0.146B 0.00
Fonar (FONR) United States $0.139B 7.33
Chembio Diagnostics (CEMI) United States $0.098B 0.00
United-Guardian (UG) United States $0.094B 20.65
InfuSystems Holdings (INFU) United States $0.090B 0.00
Surface Oncology (SURF) United States $0.075B 0.00
Trinity Biotech (TRIB) Ireland $0.060B 20.75
Oramed Pharmaceuticals (ORMP) United States $0.058B 0.00
MRI INTERVENTNS (MRIC) United States $0.052B 0.00